Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03287817 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma

ALEXANDER
Start date: September 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety and efficacy of AUTO3 a CAR T cell treatment targeting CD19 and CD22 followed by limited duration of consolidation with anti-PD1 antibody in patients with DLBCL

NCT ID: NCT03283423 Not yet recruiting - Lymphoma Clinical Trials

Image-guided Lymphadanectomy in AMIGO

Start date: November 2017
Phase: N/A
Study type: Interventional

To perform image-guided laparoscopic intra-abdominal lymph node biopsy with goal of minimizing surgical risk and improving accuracy of biopsy.

NCT ID: NCT03283202 Not yet recruiting - Clinical trials for Diffuse B-Cell Lymphoma

Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

Start date: September 21, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is Phase 1/2 study of CC-122 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, for first-line treatment of patients with Diffuse B-Cell Large B-Cell Lymphoma (DLBCL) that has poor risk factors. Approximately 40% of patients diagnosed with DLBCL are not cured with R-CHOP alone and would need additional treatment for DLBCL in the future. The addition of the experimental drug CC-122 with R-CHOP could help in controlling DLBCL in this patient population.

NCT ID: NCT03283137 Not yet recruiting - CLL Clinical Trials

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

Start date: October 2017
Phase: Phase 1
Study type: Interventional

This study will be a standard 3+3 design with a lead in of TGR-1202 at dose of 600mg (dose level 1) or 800mg daily (dose level 2) for 6 weeks, i.e. 2 cycles, followed by pembrolizumab at 200mg every 3 weeks for 8 cycles along with TGR-1202 for patients with relapsed/refractory B-cell NHL or CLL. If the dose of 600mg daily of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased to 800mg qd which is the only and final dose escalation. If TGR-1202 is not tolerated at 600mg daily the dose will be decreased to 400mg daily. The lead in of TGR-1202 was chosen to ensure clinical benefit and to minimize the occurrence of early overlapping toxicity with pembrolizumab as most toxicities were observed early on in the treatment with idelalisib, a related PI3K-inhibitor, and rituximab.

NCT ID: NCT03283111 Not yet recruiting - Lymphoma Clinical Trials

Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Start date: September 2017
Phase: N/A
Study type: Interventional

This is a retrospective, single-center, non-randomized, non-controlled study. This study aims to explore the effect of T-lymphocyte subsets changes in immunologic reconstitution and prognosis in lymphoma patients who were treated by autologous stem cell transplantation.

NCT ID: NCT03282396 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease

Start date: February 2018
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if ibrutinib can help to control mantle cell lymphoma (MCL). The safety of this drug will also be studied.

NCT ID: NCT03281551 Recruiting - B-cell Lymphoma Clinical Trials

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

Start date: October 1, 2017
Phase: Phase 1
Study type: Interventional

The major aim of this research is to assess the feasibility, safety and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma patients who have applied it.

NCT ID: NCT03278782 Not yet recruiting - Clinical trials for Cutaneous T-cell Lymphoma

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Start date: November 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if it is safe to give pembrolizumab in combination with romidepsin to patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma. Researchers also want to learn if the study drug combination can help to control the disease.

NCT ID: NCT03277729 Not yet recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Immunotherapy After Chemotherapy in Treating Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Start date: November 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this research is to find the best dose of genetically modified T-cells, to study the safety of this treatment, and to see how well it works in treating patients with B cell non-Hodgkin lymphoma that has come back or did not respond to previous treatment.

NCT ID: NCT03276468 Not yet recruiting - Follicular Lymphoma Clinical Trials

Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Start date: November 2017
Phase: Phase 2
Study type: Interventional

This study is a multicenter phase II trial which primary objective is to assess the anti-lymphoma activity of atezolizumab associated with a BCL-2 inhibitor (GDC-199, venetoclax) and an anti-CD20 monoclonal antibody (obinutuzumab) in three separate cohorts: - relapsed/refractory follicular lymphoma (FL) patients - relapsed/refractory aggressive (DLBCL) lymphoma patients - relapsed/refractory other indolent (iNHL) lymphoma patients (MZL and MALT)